{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:23:10Z","timestamp":1759710190561,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005247","name":"The University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.mehy.2021.110559","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T12:26:37Z","timestamp":1616502397000},"page":"110559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aminoglycosides and their potential as SARS-CoV-2 antivirals"],"prefix":"10.1016","volume":"150","author":[{"given":"Nevio","family":"Cimolai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2021.110559_b0005","doi-asserted-by":"crossref","first-page":"109984","DOI":"10.1016\/j.mehy.2020.109984","article-title":"Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: plausible mechanism for repurposing strategy","volume":"144","author":"Chalichem","year":"2020","journal-title":"Med Hypotheses"},{"issue":"12","key":"10.1016\/j.mehy.2021.110559_b0010","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1128\/AAC.35.12.2630","article-title":"Hygromycin B inhibits syntheses of murine coronavirus RNA","volume":"35","author":"Macintyre","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.mehy.2021.110559_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/vr.135.8.177","article-title":"Antiviral studies of feline infectious peritonitis virus in vitro","volume":"135","author":"Barlough","year":"1994","journal-title":"Vet Rec"},{"issue":"4","key":"10.1016\/j.mehy.2021.110559_b0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/104063879500700420","article-title":"Plaque variations in clinical isolates of bovine coronavirus","volume":"7","author":"Kapil","year":"1995","journal-title":"J Vet Diagn Invest"},{"issue":"10","key":"10.1016\/j.mehy.2021.110559_b0025","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1128\/AAC.35.10.2125","article-title":"Hygromycin B therapy of a murine coronaviral hepatitis","volume":"35","author":"Macintyre","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.mehy.2021.110559_b0030","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0042-6822(86)90214-X","article-title":"Increased sensitivity of virus-infected cells to inhibitors of protein synthesis does not correlate with changes in plasma membrane permeability","volume":"155","author":"Cameron","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.mehy.2021.110559_b0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-0-387-33012-9_34","article-title":"Viroporin activity of SARS-CoV E protein","volume":"581","author":"Liao","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.mehy.2021.110559_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbrc.2021.01.013","article-title":"RNA sequence and binding alter conformational profile of SARS-CoV-2 stem loop II motif","volume":"545","author":"Aldumani","year":"2021","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1016\/j.mehy.2021.110559_b0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijid.2020.06.063","article-title":"Paromomycin: a potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19","volume":"98","author":"Tariq","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.mehy.2021.110559_b0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jmv.25752","article-title":"Potentially repurposing adamantanes for COVID-19","volume":"92","author":"Cimolai","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.mehy.2021.110559_b0055","article-title":"Complicating infections associated with common endemic human respiratory coronaviruses","author":"Cimolai","year":"2020","journal-title":"Health Secur"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:23:52Z","timestamp":1759692232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":11,"alternative-id":["S0306987721000773"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110559","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminoglycosides and their potential as SARS-CoV-2 antivirals","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110559"}}